The ability of sodium-glucose cotransporter 2 inhibitor Canagliflozin to inhibit glucose uptake in HCC cells expands its potential applications beyond diabetes management, offering promise for patients with HCC [232]. Here, SLC5A2 is linked to hepatocellular carcinoma.